🔍 See what insiders are buying — free 7-day trial, no credit card required.
Get started →
MRNA
NASDAQ
🇺🇸 US
Moderna, Inc.
Pharmaceuticals
32Score
DipBuster Score™
$55.14
+$0.32 (+0%)
Live price · Source: FMP-live
52-Week Position
$22.28
52% of range
$85.60
Beta
0.942
Market-like
Dividend
—
no income
Mkt Cap
$21.88B
total value
Mkt Cap$21.88B
P/EN/A
DividendNone
Beta0.942
52W High$85.60
52W Low$22.28
DipBuster Brief
Key signals at a glance
Zone: Hold / Watch
Neutral
Mid-Range Position (52% of 52-Week Range)
The stock sits in the middle of its annual range — no extreme dip opportunity, but also not overextended.
Neutral
Earnings Data Unavailable
P/E ratio could not be determined — this is common for early-stage, loss-making, or recently-listed companies.
Valuation
P/E Ratio—
Mkt Cap$21.88B
52W Position52% of range
EV/EBITDA—
Cash Flow
FCF Yield—
FCF / Share
Op. Cash Flow—
Margins
Gross Margin—
Op. Margin—
Net Margin—
Balance Sheet
Cash—
Total Debt—
Net Cash—
Dividend
Yield—
Annual / shNone
Beta0.942
🔒
FCF, margins & balance sheet data are hidden — create a free account to see them.
🕵️ Insiders
📊 Valuation
💰 Dividends
📰 News
🤖 AI Analysis
Recent director dealings and insider transactions at Moderna, Inc. (MRNA), from SEC Form 4 filings. Open-market buys by directors spending their own money are one of the strongest signals in investing.
| Date | Insider | Type | Shares |
|---|---|---|---|
| 2026-07-15 | Hoge Stephen | SELL | 16,110 |
| 2026-07-15 | Hoge Stephen | SELL | 37,226 |
| 2026-07-15 | Hoge Stephen | SELL | 53,336 |
| 2026-07-15 | Hoge Stephen | BUY | 16,110 |
| 2026-07-15 | Hoge Stephen | BUY | 37,226 |
| 2026-07-08 | Mcdonnell Michael R. | BUY | 5,733 |
| 2026-07-08 | Mcdonnell Michael R. | BUY | 1,618 |
| 2026-07-08 | Mcdonnell Michael R. | BUY | 7,415 |
| 2026-07-05 | Banque Soria Ester | BUY | 38,364 |
| 2026-07-05 | Banque Soria Ester | BUY | 18,658 |
Graham NCAV Analysis
Above net-net level
Current Assets$6.54B
Less: Total Liabilities−$3.69B
= Net Current Asset Value$2.86B
NCAV Per Share$7.2487
Current Price$55.81
Price / NCAV7.70×
Margin of Safety-669.9%
Computed from 2025-12-31 balance sheet (Yahoo Finance). NCAV = current assets − total liabilities. Verify against the latest report.
Valuation
P/E RatioN/A
Market Cap$21.88B
Beta0.942
Dividend/yrNone
52W High$85.60
52W Low$22.28
52-Week Range
$22.28Now$85.60
52% through annual range
From 52W High−35.6%
From 52W Low+147.5%
📖 Plain English Summary
Moderna, Inc. is at 52% of its 52-week range. Beta 0.942 — tends to move less than the market.
🏦 Analyst Price Target
Loading…
🎯 Analyst Revenue & EPS Estimates
Loading estimates…
🔄 Peer Comparison
Loading peers…
Loading dividend data…
Latest news for MRNA
🟢 Bullish
⬜ Neutral
🔴 Bearish
🤖
DipBuster AI Analysis — MRNA
Heuristic · balance sheet, insider filings, price data, academic research
Moderna, Inc. — DipBuster Score 32/100
Graham value assessment, NCAV analysis, price zones...
Insider signals, cluster detection, risk factors...
Track Moderna, Inc. free
Add MRNA to a watchlist, set insider-buy and price alerts, and get the full financial picture — free account, no card.
Sponsored · FCA Regulated Broker
Freetrade
Simple investing app. Free ISA. UK and US stocks. FCA regulated.
Free share when you fund your account
Capital at risk. Your investments can go down as well as up. Disclaimer
DipBuster Score™ Breakdown
Value & P/E
0/30
Dip Position
19/25
Momentum & Volume
8/25
Quality & Size
5/10
Insider Activity
0/10
🎯 Dip Buyer Signal
22
/100 · NEUTRAL
dip depth
4/25
oversold rsi
9/25
mean reversion
8/15
insider zone
0/25
capitulation
0/10
Technical signal only. Not financial advice.
Quick Take
⚪
Not a Dip
DipBuster Score: 32/100
📊
Run a full check in the AI analysis tab for a deeper look.
Company Profile
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts targ…
Sector
Pharmaceuticals
Market
🇺🇸 US
CEO
Stéphane Bancel
Staff
4,700 employees
Website